Melola Discovery

← Melola Discovery

Jurnal SINTA 1

The Role of Colchicine in Acute Coronary Syndrome

Heart Science Journal · Vol. 1 No. 4 (2020) · hlm. 4–8

DOI
10.21776/ub.hsj.2020.001.04.02
ISSN
2721-9984, 2721-9976
Terbit
2020-12-23
Penerbit
Universitas Brawijaya
Bahasa
en

Abstrak

Background: Despite the advances of current optimal treatment of atherosclerotic disease, the incidence of events after acute coronary syndrome (ACS) remains high. Colchicine, with its well-established pleiotropic anti-inflam- matory effects, may inhibit NLRP3 inflammasome, a key mediator in atherosclerosis-associated inflammation (AAI) thus reducing systemic inflammation. NRLP3 inflammasome activation inside leukocytes (mainly monocytes and neutrophils) is precipitated by cholesterol crystals that are present in all atherosclerosis stages. ô°Ÿô°‹ô°¡ô°ˆô°‡ô±Žô°‹ô°‡ô°†ô°‚ ô°ô°€ô°‚ô°…ô°©ô°ô°‚ô°…ô°ƒô°† ô°ƒô°œ ô°¢ô°Žô°ƒô°ô°…ô°†ô°œô°ô°ô°ô°ô°ô°‚ô°ƒô°Žô° ô°€ô°ô°‚ô°ƒô°„ô°…ô°†ô°‡ô°ˆ ô°ˆô°‹ô°€ô°Œ ô°ô°ˆ ô°…ô°†ô°‚ô°‡ô°Žô°ô°‡ô°‹ô°„ô°…ô°†ô°ô°‘ô°’ ô°ô°†ô°— ô°…ô°†ô°‚ô°‡ô°Žô°ô°‡ô°‹ô°„ô°…ô°†ô°ô°‘ô°£ ô°³ô°…ô°ô° ô°œô°ƒô°ô°ô°ƒô°³ô°¨ ô°˜ô°Œô°‡ô°ˆô°‡Â cytokines are the crucial inflammatory pathway mediators that promote the formation of plaque and instability in the inflammatory cascade.Objective: This review will elaborate on the function of immune cells in atherosclerosis, explain the mechanisms of NLRP3 inflammasome activation in the context of AAI, and address the possible role of colchicine specifically targeting NLRP3 inflammasome and its concomitant downstream mediators in ACS, and provide an overview of current or ongoing studies produced in this area.DiscussionÂ: NRLP3 inflammasome activation inside leukocytes (mainly monocytes and neutrophils) is precipitat- ed by cholesterol crystals that are present in all atherosclerosis stages. Subsequent activation of pro-inflammatory ô°€ô°ô°‚ô°ƒô°„ô°…ô°†ô°‡ô°ˆ ô°ˆô°‹ô°€ô°Œ ô°ô°ˆ ô°…ô°†ô°‚ô°‡ô°Žô°ô°‡ô°‹ô°„ô°…ô°†ô°ô°‘ô°’ ô°ô°†ô°— ô°…ô°†ô°‚ô°‡ô°Žô°ô°‡ô°‹ô°„ô°…ô°†ô°ô°‘ô°£ ô°³ô°…ô°ô° ô°œô°ƒô°ô°ô°ƒô°³ô°¨ ô°˜ô°Œô°‡ô°ˆô°‡ ô°€ô°ô°‚ô°ƒô°„ô°…ô°†ô°‡ô°ˆ ô°ô°Žô°‡ ô°‚ô°Œô°‡ ô°€ô°Žô°‹ô°€ô°…ô°ô° ô°…ô°†ô°œô°ô°ô°ô°ô°ô°‚ô°ƒô°Žô°Â pathway mediators that promote the formation of plaque and instability in the inflammatory cascade. A potential advantage of a medication acting through an inflammatory milieu found in atherosclerotic lesions has recently become the need for novel therapeutic options. Colchicine, with its well-established pleiotropic anti-inflammato- ry effects, may inhibit NLRP3 inflammasome, a key mediator in atherosclerosis-associated inflammation (AAI) thus reducing systemic inflammation.Conclusion: Colchicine is a safe and reliable medication for ACS patients, alongside reveal various benefit in reducing inflammation through inhibition of NLRP3 Inflammasome`

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 287 tautan kepenulisan bersama · 13 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Brawijaya
  • RSUD Prof. Dr. Saiful Anwar Malang
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Mohammad Saifur RohmanUniversity of Brawijaya44
Setyasih AnjarwaniUniversity of Brawijaya31
Anna Fuji RahimahUniversity of Brawijaya25
Novi KurnianingsihUniversity of Brawijaya23
Cholid Tri TjahjonoUniversity of Brawijaya22
Ardian RizalUniversity of Brawijaya16
Sasmojo WiditoUniversity of Brawijaya14
Heny MartiniUniversity of Brawijaya12
Muhammad Rizki FadlanUniversity of Brawijaya7
Putri Annisa KamilaUniversity of Brawijaya6
Wella KarolinaUniversity of Brawijaya5
Yoga WaranugrahaUniversity of Brawijaya5
Tria Yudha NugrahaUniversity of Brawijaya4
Hayla Iqda MillisaniUniversity of Brawijaya4
Valerinna YogibuanaAfiliasi tidak diketahui4
Anna Fuji RahimahAfiliasi tidak diketahui4
Yudi Putra ApridityaUniversity of Brawijaya4
Teguh AryanugrahaUniversity of Brawijaya4
Muhammad Saifur RohmanAfiliasi tidak diketahui4
Danti Utami SetyowatiRSUD Prof. Dr. Saiful Anwar Malang3
Dadang HendrawanUniversity of Brawijaya3
Dea Arie KurniawanUniversity of Brawijaya3
Seprian WidasmaraUniversity of Brawijaya3
Valerinna Yogibuana Swastika PutriUniversity of Brawijaya3
Shalahuddin Suryo BaskoroUniversity of Brawijaya3
Lutfi Hafiz ZunardiUniversity of Brawijaya3
Yuri AfifahUniversity of Brawijaya3
Yoseph Budi UtomoUniversity of Brawijaya3
Ayu Asri Devi AdityawatiUniversity of Brawijaya3
Harris KristantoUniversity of Brawijaya2
Taufieq Ridlo MakhmudUniversity of Brawijaya2
Faris Wahyu NugrohoUniversity of Brawijaya2
Anita Surya SantosoAfiliasi tidak diketahui2
Imelda KrisnasariUniversity of Brawijaya2
Nikhen NoverikeUniversity of Brawijaya2
Imam Mi'raj SuprayogaUniversity of Brawijaya2

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://heartscience.ub.ac.id/index.php/heartscience/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">The Role of Colchicine in Acute Coronary Syndrome</dc:title>
	<dc:creator xml:lang="en">Adrian, Liemena Harold</dc:creator>
	<dc:creator xml:lang="en">Satrijo, Budi</dc:creator>
	<dc:creator xml:lang="en">Sargowo, Djanggan</dc:creator>
	<dc:creator xml:lang="en">Prasetya, Indra</dc:creator>
	<dc:subject xml:lang="en">colchicine</dc:subject>
	<dc:subject xml:lang="en">acute coronary syndrome</dc:subject>
	<dc:subject xml:lang="en">inflammasome</dc:subject>
	<dc:subject xml:lang="en">inflammation</dc:subject>
	<dc:subject xml:lang="en">NLRP3</dc:subject>
	<dc:description xml:lang="en">Background: Despite the advances of current optimal treatment of atherosclerotic disease, the incidence of events after acute coronary syndrome (ACS) remains high. Colchicine, with its well-established pleiotropic anti-inflam- matory effects, may inhibit NLRP3 inflammasome, a key mediator in atherosclerosis-associated inflammation (AAI) thus reducing systemic inflammation. NRLP3 inflammasome activation inside leukocytes (mainly monocytes and neutrophils) is precipitated by cholesterol crystals that are present in all atherosclerosis stages. 􏰟􏰋􏰡􏰈􏰇􏱎􏰋􏰇􏰆􏰂 􏰍􏰀􏰂􏰅􏰩􏰍􏰂􏰅􏰃􏰆 􏰃􏰜 􏰢􏰎􏰃􏰐􏰅􏰆􏰜􏰏􏰍􏰝􏰝􏰍􏰂􏰃􏰎􏰁 􏰀􏰁􏰂􏰃􏰄􏰅􏰆􏰇􏰈 􏰈􏰋􏰀􏰌 􏰍􏰈 􏰅􏰆􏰂􏰇􏰎􏰏􏰇􏰋􏰄􏰅􏰆􏰐􏰑􏰒 􏰍􏰆􏰗 􏰅􏰆􏰂􏰇􏰎􏰏􏰇􏰋􏰄􏰅􏰆􏰐􏰑􏰣 􏰳􏰅􏰏􏰏 􏰜􏰃􏰏􏰏􏰃􏰳􏰨 􏰘􏰌􏰇􏰈􏰇 cytokines are the crucial inflammatory pathway mediators that promote the formation of plaque and instability in the inflammatory cascade.Objective: This review will elaborate on the function of immune cells in atherosclerosis, explain the mechanisms of NLRP3 inflammasome activation in the context of AAI, and address the possible role of colchicine specifically targeting NLRP3 inflammasome and its concomitant downstream mediators in ACS, and provide an overview of current or ongoing studies produced in this area.Discussion : NRLP3 inflammasome activation inside leukocytes (mainly monocytes and neutrophils) is precipitat- ed by cholesterol crystals that are present in all atherosclerosis stages. Subsequent activation of pro-inflammatory 􏰀􏰁􏰂􏰃􏰄􏰅􏰆􏰇􏰈 􏰈􏰋􏰀􏰌 􏰍􏰈 􏰅􏰆􏰂􏰇􏰎􏰏􏰇􏰋􏰄􏰅􏰆􏰐􏰑􏰒 􏰍􏰆􏰗 􏰅􏰆􏰂􏰇􏰎􏰏􏰇􏰋􏰄􏰅􏰆􏰐􏰑􏰣 􏰳􏰅􏰏􏰏 􏰜􏰃􏰏􏰏􏰃􏰳􏰨 􏰘􏰌􏰇􏰈􏰇 􏰀􏰁􏰂􏰃􏰄􏰅􏰆􏰇􏰈 􏰍􏰎􏰇 􏰂􏰌􏰇 􏰀􏰎􏰋􏰀􏰅􏰍􏰏 􏰅􏰆􏰜􏰏􏰍􏰝􏰝􏰍􏰂􏰃􏰎􏰁 pathway mediators that promote the formation of plaque and instability in the inflammatory cascade. A potential advantage of a medication acting through an inflammatory milieu found in atherosclerotic lesions has recently become the need for novel therapeutic options. Colchicine, with its well-established pleiotropic anti-inflammato- ry effects, may inhibit NLRP3 inflammasome, a key mediator in atherosclerosis-associated inflammation (AAI) thus reducing systemic inflammation.Conclusion: Colchicine is a safe and reliable medication for ACS patients, alongside reveal various benefit in reducing inflammation through inhibition of NLRP3 Inflammasome`</dc:description>
	<dc:publisher xml:lang="en">Universitas Brawijaya</dc:publisher>
	<dc:date>2020-12-23</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://heartscience.ub.ac.id/index.php/heartscience/article/view/140</dc:identifier>
	<dc:identifier>10.21776/ub.hsj.2020.001.04.02</dc:identifier>
	<dc:source xml:lang="en">Heart Science Journal; Vol. 1 No. 4 (2020): Acute Coronary Syndrome in Daily Practice : Diagnosis, Complication, and Management; 4-8</dc:source>
	<dc:source>2721-9984</dc:source>
	<dc:source>2721-9976</dc:source>
	<dc:source>10.21776/ub.hsj.2020.001.04</dc:source>
	<dc:language>en</dc:language>
	<dc:relation>https://heartscience.ub.ac.id/index.php/heartscience/article/view/140/306</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2020 Liemena Harold Adrian, Budi Satrijo, Djanggan Sargowo, Indra Prasetya</dc:rights>
</oai_dc:dc>